Intervention

Pasireotide LAR

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common conditions10

Lead sponsors shown2

Clinical trials

2 shown

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA TrialNCT01563354 · 2013-08-16

COMPLETED

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesNCT01794793 · 2013-06-10

COMPLETED

Common conditions

Acromegaly1 Cushing's Disease1 Dumping Syndrome1 Ectopic ACTH Secreting (EAS) Tumors1 Melanoma Negative for bRAF1 Melanoma Negative for nRAS1 Neuroendocrine Carcinoma of the Lung and Thymus1 Neuroendocrine Tumors1 Pituitary Tumors1 Prostate Cancer1

Leading sponsors

Novartis Pharmaceuticals 1 RECORDATI GROUP 1

Trial status mix

COMPLETED2

Phase mix

PHASE21

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.